5th Annual Gene Therapy Immunogenicity is a conference that covers topics such as:
- The impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon
- Developing an immune evasive AAV for repeat dosing
- Performances of biosafety analytical assays commonly used in gene therapy development
- Strategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics
- How to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis
- Immunogenicity risk assessment for AAV-based gene therapies with Roche
- Regulatory considerations for immune responses to gene therapies with the FDA
5th Annual Gene Therapy Immunogenicity might be held in Boston, United States in 2024.
